China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Pharmaceutical Group Ltd. is set to become the largest shareholder in Tasly Pharmaceuticals by acquiring a 28% stake, amounting to over 418 million shares, for a total consideration of approximately RMB 6.21 billion (HK$6.8 billion). The transaction, which is classified as a discloseable transaction under the listing rules, is currently conditional and not guaranteed to proceed, urging shareholders and potential investors to trade with caution.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
